GoodRx (NASDAQ:GDRX) Shares Down 6% – Time to Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX) was down 6% during trading on Wednesday . The stock traded as low as $2.29 and last traded at $2.2550. Approximately 431,567 shares were traded during trading, a decline of 87% from the average daily volume of 3,441,525 shares. The stock had previously closed at $2.40.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Mizuho cut their price target on GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, February 27th. Jefferies Financial Group cut GoodRx to a “hold” rating in a report on Thursday, January 22nd. Barclays started coverage on shares of GoodRx in a report on Monday, December 8th. They issued an “underweight” rating and a $3.00 target price on the stock. Morgan Stanley dropped their price objective on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. Five equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.98.

GoodRx Stock Down 6.5%

The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.78. The firm’s 50-day moving average price is $2.44 and its 200 day moving average price is $3.16. The firm has a market cap of $762.02 million, a P/E ratio of 24.95, a price-to-earnings-growth ratio of 1.63 and a beta of 1.52.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.09. The firm had revenue of $194.79 million during the quarter, compared to analyst estimates of $193.27 million. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. GoodRx’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.09 EPS. As a group, research analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock valued at $38,947,000 after buying an additional 624,182 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of GoodRx by 4.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock worth $24,001,000 after buying an additional 184,734 shares in the last quarter. LSV Asset Management lifted its stake in shares of GoodRx by 20.0% in the 4th quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock worth $7,658,000 after acquiring an additional 471,319 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of GoodRx by 6.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company’s stock worth $7,183,000 after acquiring an additional 152,934 shares during the period. Finally, Prescott Group Capital Management L.L.C. bought a new position in shares of GoodRx in the fourth quarter valued at approximately $4,812,000. 63.77% of the stock is currently owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.